Cargando…
PReS-FINAL-2139: Tapering and withdrawal of tocilizumab in patients with systemic JIA in inactive disease: results from an alternative dosing regimen in the tender study
Autores principales: | De Benedetti, F, Ruperto, N, Brunner, HI, Grom, A, Wulffraat, N, Henrickson, M, Jerath, R, Kimura, Y, Kadva, AK, Wang, J, Martini, A, Lovell, D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4042215/ http://dx.doi.org/10.1186/1546-0096-11-S2-P151 |
Ejemplares similares
-
Tapering and withdrawal of tocilizumab in patients with systemic juvenile idiopathic arthritis in inactive disease: results from an alternative dosing regimen in the TENDER study
por: De Benedetti, F, et al.
Publicado: (2014) -
PReS-FINAL-2159: Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients
por: Lu, P, et al.
Publicado: (2013) -
Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA): TENDER 52-week data
por: De Benedetti, Fabrizio, et al.
Publicado: (2012) -
PReS-FINAL-2188: Insulin sensitivity is improved in sjia children with insulin resistance after tocilizumab treatment: results from the tender study
por: Mirjafari, H, et al.
Publicado: (2013) -
PReS13-SPK-1576: Unmeet needs in JIA treatment
por: Ruperto, N
Publicado: (2013)